NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ...
The environmental problems caused by adverse effects of plastics and other materials has increased interest for bio-based materials. In this context, projects such as the EU funded BioMonitor set out ...
Statistical classifications generally follow relevant policy and societal trends. There are therefore opportunities to add statistical codes for bio-based products and materials to statistical ...
Public genetic databases could have a discrepancy in identifying BRCA1 and BRCA2 variant classifications, which can introduce uncertainty and diminish patient care, according to a study by Myriad ...
Robert D. Montoya examines how biodiversity classification, with its ranking of species, has social and political implications as well as implications for the field of information studies in his book ...
The FDA has issued new risk classification orders for two series of products, including in vitro diagnostics for hepatitis C, two of which the agency down-regulated from class III to class II. However ...
* MUSTANG BIO RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT CLASSIFICATION FROM EUROPEAN MEDICINES AGENCY FOR MB-107 LENTIVIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY Source text for ...
* Atara Bio receives advanced therapy medicinal product classification for allogeneic epstein-barr virus specific cytotoxic T-Lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) Source text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results